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Abstract
Background: A number of integrase defective lentiviral (IDLV) packaging systems have been developed to produce
integration deficient lentiviruses for gene delivery and epichromosomal expression. However, despite their growing
demand, a comparative study to systemically evaluate the performance efficiency of different mutants on virus
packaging and gene expression has not been done.
Results: Site-directed mutagenesis was used to generate five integrasedeficient mutants for non-integrative lentiviral
packaging (NILVP). The five mutants were then individually incorporated to make different integrase defective lentivirus
plasmid packaging mix, keeping other packaging factors constant. CD511B-1, a lentivectorexpressing GFP from an EF1
promoter, was packaged with each of the five different lentivirus packaging mix to make pseudotypedviral particles.
The performance and packaging efficiency of each of the integrase deficient mutants was evaluated based on GFP
expression in HT1080 cells, while the wild type lentivirus packaging mix was used as a control. Of the five integrase
mutant candidates, one with the highestGFP transgene expression level was chosen for further characterization. The
non-integrative nature of this candidate was confirmed by quantitative polymerase chain reaction and characterized
using both dividing and non-dividing cells. Finally, a detailed standard protocol for NILVP using this integrase defective
mutant was developed.
Conclusions: An efficient lentiviral packaging system for producing on-integrative lentivirus was established. This system
is compatible with most existing lentivectors and can be used to transduce both dividing and non-dividing cells.
Keywords: Integrase defective lentivirus, lentiviral package, viral transduction
Background
Lentiviral vectors provide one of the most effective gene
delivery systems that have a broad range of applications-
frombasic research to gene therapy [1–3]. For instance,
HIV-basedlentivectorshave been extensively used for
stably expressing different effector molecules, including
cDNA, siRNA, long non-coding RNA, DNA fragment,
antisense, ribozyme, and transcriptional reporter [4–6].
Recently, lentiviral vectors have been used clinically to
express chimeric antigen receptor (CAR) in T lymph
cells, enabling CAR-T cells in curing end-stage B cell
leukemia [7, 8]. By packaging the lentiviral construct
into pseudoviral particles, an efficient transduction can
be achieved even with the most difficult cell types, such
as primary cells, stem cells and hematopoietic cells
[1, 2]. Lentivectorsalsohave a larger gene-cargocapacity
(~7–8 kb) with low immunogenicity compared to other
delivery vehicles. The major disadvantage of lentivectorsi-
sits ability to integrate into the genome, which can lead to
insertion mutations and other side effects [1, 9].
To circumvent this, one can generate non-integrative
lentivirusesthat remain in the cell epichromosomally.
This episomal vector can retain all the advantages of
lentivectorsand express transgene of interest without
causinginsertional mutations. There are several methods
to generate non-integrative lentivirus and one such ap-
proach is to mutate the integrase gene. Although studies
have identified several critical amino-acids for generating
so called integrase defective lentivirus (IDLV) [10–12], a
comparative study to systemically evaluate their relative
performance on gene expressionislacking.
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To make lentiviral particles, lentivectors which carry
the transgene of interest (in this case GFP under a
constitutive promoter EF1α, CD511B-1) is mixed with a
plasmid packaging mix which includes the integrase,
envelope gene and other genes necessary to generate
pseudoviralparticles. This plasmid mix is then co-
transfected into a 293 T producer cell line. Viral harvest
is done 48 h and 72 h post transfection. In this study, we
designed and generated a cohort of integrase mutants by
site directed mutagenesis. We then evaluated the pack-
aging efficiency of each of the mutants when combined
with rest of the lentivirus packaging plasmids and identi-
fied one with the highest packaging efficiency. We
further evaluated and characterized this mutant for its
ability totransduceboth dividing and non-dividing cells.
Since the mutation occurs in one of the packaging plas-
mids, this system is likely compatible with most existing
lentivectors, hence providing an efficient and robust
system for IDLV production.
Results and Discussion
Lentiviral Packaging System and IDLV Production
Currently, the most efficient technology for producing
high titer, replication-incompetent, and infectious
lentiviral particles, is based on transient and coordinated
expression of a lentiviral vector along with plasmids
expressing all the necessary packaging proteins delivered
into producer cells by simultaneous transfection [13].
When expressed in packaging cells, the lentivector
produces large number of the transcriptcontaining all
functional elementsrequired for efficient packaging, in-
cluding cPPT, Psi and RRE [13]. In order to be compatible
with existing lentiviral vectors, we chose to modify one of
the packaging proteins, polymerase (pol) for IDLV pro-
duction. The polymerase contains both the polymerase
domain and the integrase domain for efficient integration
of transgene into the genome. Specifically, we mutated
three critical amino-acids and one triplet of integrase
within the pol gene. A schematic diagram is shown in
Fig. 1a, where the location of the mutations in the
Integrase domain is shown. These mutations will produce
defective integrase during lentiviral packaging. The inte-
grase defective Pol plasmid can now be used to produce
integrase defective lentiviral particles, without requiring
any further modifications to the lentivector backbone.
We initially generated 5 different mutants in the
integrase gene (Fig. 1a) and selected the best per-
former with respect to gene expression. To achieve
Fig. 1 System design and screening of IDLV. Schematic representation of the HIV-1 integrase domain and its basic region (a). Numbers correspond to
amino acid position of integrease domain. Site-directed mutagenesis resulted in mutation of the wild-type amino acids (bold black letters) to mutants
(bold red letters). An illustration of a lenti-reporter used to assess the transduction and expression of each mutant. The reporter has dual promoter,
CMV and EF1α, MCS are multiple cloning sites for potential insertion of gene of interest. PolyA isthe signaling sequences of polyadenylation (b).
HT1080 cells were imaged after 72 h transduction and the best performer in mutant group was highlighted in red (c)
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this, we used a previously established green fluorescent re-
porter expressed under EF1α promoter CD511B-1 as a
read-out (Fig. 1b). We usedWT Integrase and candidate
Integrase mutants along with Gag and VSVG packaging
plasmid mix to package CD511 under identical experi-
mental conditions. As shown in Fig. 1c, all mutant
candidates express GFP at varying levels, albeit much
lower than the GFP expressionfromthe WT control,
whichissimilar to published reports [10–12]. Among them,
mutant D116Ademonstrated the highest levels of reporter
expression (Fig. 1c). Since we used the same amount of
infectious viral particles to perform the transduction, we
selected mutant D116A for further characterization.
To test if mutant D116A could express other trans-
genes, we used a different lentivector reporter combin-
ation, a mouse stem cell viral promoter driven dual
reporter construct MSCV-GFP-T2A-RFP (LV605VA-1),
Following viral transduction, the MSCV-driven GFP-
RFP fusion vector expressed GFP and RFP, suggesting
that D116A mutant is able to produce IDLV viruses for
transgene expression using a different promoter and
reporter (Fig. 2). Based on the results above, we were
able to identify and confirm the best mutant among
these five integrase mutants. This mutant (D116A) can
be used to package IDLV for gene transduction and
expression in mammalian cells. The information
concerning the expression vector of mutant D116A and
its encoding sequences is provided in Additional file 1:
Figure S1.
D116A Mutant Produces IDLV with Non-Integration Nature
To rule outthe possibility that the D116A mutant may
produce integrative lentiviral particles rather than non-
integrative lentivirus, we next carried out a comparative
transduction experiment on HT1080 cells. After transdu-
cingcultured cells with GFP reporter virus CD511VB-1,
both the wild-type and integrase defective viral particles
showed GFPexpression at Day 3 (Fig. 3a). If D116Amutant
produced true non-integrative IDLVparticles, the copy
numbers of the transgene would decrease with every cell
division and passage, since transgenes are episomal and
cannot replicate along with the genomic DNA. Alterna-
tively, if they do integrate into the genomic DNA, they will
be able to replicate along with cell growth and division.
Therefore, we conducted a quantitative real-time PCR
analysis to examine the relative copy numbers of trans-
genes. While the WT integrase virusshowed an initial
decrease in copy number at passage 6, which was rela-
tively stable until passage 9, D116A mutant demonstrated
a steady decrease in copy numbers that were close to
Fig. 2 A comparative study of WT and IDLV. a lentivector expressing GFP and RFP from MSCV promoter (LV605A-1) was packaged with wild-type
and mutant integrase; WPRE are woodchuck hepatitis virus-derived posttranscriptional regulatory element for stabilizing the transcripts. The same
amount of packaged psudoviruses was used to transduce HT1080 cells. b Images were taken at Day 3 after transduction
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levels of the non-infected control (Fig. 3b). Thus, D116A
mutant produces non-replicable and non-integrative
lentiviral particles, which is consistent with results from
previous reports using either PCR or Southern blot
analysis [10–12].
IDLV Tranducesboth Dividing and Non-Dividing Cells
We next examined the performance of IDLV for
transducing dividing and non-dividing cells. To study
transgene expression in dividing cells, we transduced
HT1080 with GFP reporter virus (CD511VB-1), and
compared the relative expression levels between wild-
type and mutant viruses by monitoring their GFP
expression. As shown in Fig. 4, HT1080 cells transduced
with WT CD511 virus produced high levels of GFP
expression through 3 passages, suggesting permanent
expression due to transgene integration. In contrast,
HT1080 cells transduced with the integrase defective
mutant CD511 virus resulted in an initial expression of
GFP, followed by a steady decrease in both the intensity
of GFP expression levels and percentage of GFP positive
cells (Fig. 4 right panel). These results were consistent
with previous reports [10–12], indicating the transient
expression nature of IDLV when used to transduce
dividing cells.
We next assessed the performance of IDLV transduction
in non-dividing cells where the transgene should remain
stable. We first prepared non-dividing cells by treating the
mouse embryonic fibroblast cell (STO) with actinomycin
[14]. Subsequently we performed transduction with
theMSCV-GFP-RFP dual reporter virus, resulting in ex-
pression of both GFP and RFP in these non-dividing STO
cells. The GFP and RFP expression were persistent and
even increased slightly up to Day 18 after transduction
(Fig. 5), showing that transgene expression is relatively
stable in those non-dividing cells. Our results are consist-
ent with a previous study that IDLV may have a long-term
and sustainable transgene expression in non-dividing cells.
Hence these features of IDLV may be exploited when
non-proliferative tissues are targeted.
Lentivirus has been used transducing some primary
and hoard-to-transfect cells. Although we did not
provide direct evidence in this study, we expect IDLV
will follow the tropism of wild-type counterpart,
because this change occurs within the integrase
domain of POL gene, which will not directly affect
the tropism of lentivirus.
Fig. 3 Non-integrative nature of IDLV. a Expression of GFP reporter after lentiviral transduction on Day 3. b A real-time PCR analysis of relative viral
copy numbers at different passages in HT1080 cells. P-3, p-6, and p-8 are cell passage numbers counted post-transduction with WT and IDLV
reporter viruses
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Fig. 5 Transgene expression in nondividing cells. Mouse embryonic fibroblasts (STO) were treated with actinomycin to make nondividing cells.
The treated cells were subsequently transduced with IDLV reporter viruses. Images were taken using either GFP-filter (left panel), RFP-filter
(middle panel) or phase contrast (right panel) to show the reporter expression
Fig. 4 Transgene expression in dividing cells. HT1080 cells were imaged at different days after transduction. Images were taken under the same
exposure setting to compare the relative expression levels of the GFP reporter when wild-type integrase or D116A mutant were used
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IDLV Performance in Relationship with Its Cargo Size
We next determined whether gene size also influences
the gene expression level. We first generated a series of
lentivectors with increasing cargo size. To monitor gene
expression, we used the constitutive promoter EF1α to
drive the GFP reporter, and another gene expression
cassette to accommodate various sized genes under the
control of a CMV promoter. With the incorporation of
gene fragments increasing incrementally in size (Fig. 6),
we observed a steady decrease in the levels of reporter
expression. This decrease occurred in both WT and
IDLV groups, suggesting the cargo size is an important
factor when using a lentivector.
Conclusion
We have identified and validated an integrase mutant
that can be used to produce non-integrative lentiviral
particles. This IDLV system would allow researchers to
use their existing lentivectors to generate non-integrative
lentiviral particles with increased safety profile and
decreased side effect such as insertional mutation and
insertion-caused genome instability respectively.
Methods
Integrase Mutagenesis and Reporter Construction
The pPACKH1-GAG plasmid (SBI, Mountain View, CA)
contains the structural (gag), replication (pol) and
envelop (env) gene. The pol contains a functional
domain of integrase, which is responsible for provirus
integration. As shown in Fig. 1a, we designed and
synthesized primer pairs to carry out site-directed muta-
genesis using high fidelity DNA polymerase followed by
DpnI (NEB, Ipswich, MA) treatment and transformation.
The primers used for D64A (forward 5′- aggaatatggca
actagcttgtacacatttagaag-3′; reverse 5′-ctaaatgtgtacaagc
tagttgccatattcctggac), D116A (forward 5′- gtaaaaacaataca
tacagccaatggcagcaatttcacc-3′; reverse 5′- gaaattgctgccat
tggctgtatgtattgtttttactggc-3′), D152A (forward 5′-caaagt
caaggagtagtagcatctatgaataaagaattaaagaaaatt; reverse 5′-
ctttaattctttattcatagatgctactactccttgactttgggg-3′), and trip-
let mutation in basic region (forward5′-gtgacataaaagtagt
gccagcagcacatgcaaagatcattagggat-3′; reverse primer 5′-at
ccctaatgatctttgcatgtgctgctggcactacttttatgtcac- 3′). Using
different combinations of primer pairs, we have gen-
erated five integrase mutants as confirmed by double
Fig. 6 Gene expression levels decrease with incremental cargo size for both wild-type and IDLV. Viral particles were packaged with both wild-type
and mutant integrase. The same amounts of viral particles were used for transducing HT1080 cells. Images were taken at Day 3 after transduction.
LTR are long terminal repeats derived from HIV provirus
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stranded DNA sequencing (SeqeneTech, Mountain
View, California).
Cell Culture and Transduction
Human embryonic kidney HEK293-TN (LV900A-1, SBI,
Mountain View, CA) and fibrosarcoma HT1080 (ATCC,
Manassas, VA) cells were maintained in high glucose
Dulbecco’s Minimal Essential Medium (DMEM)
supplemented with 10 % FBS, 2 mMGlutaMax (Life
Technologies), 100 U/ml penicillin and 100 U/ml
streptomycin. Transduction reagent TransDux (LV850A-1,
SBI, Mountain View, CA) was used to infect cells with virus
to enhance the transducing efficiency. CD511B-1 (GFP
reporter) and LV605A-1 (DualGFP-RFP reporter) from SBI
were the constructs used to make WTand integrase defect-
ive lentiviral particles for most of the studies. These
constructs were assembled by a combination of PCR and
seamless fusion method as reported before [15, 16].
STO Culture and Actinomycin Treatment
STO cells were cultured in DMEM high-glucose (Life
Technologies), supplemented with 2 mMGlutaMax
(Life Technologies), and 1 % nonessential amino acid
(Life Technologies). Cells were treated with 10 μg/ml
actinomycin C (Sigma) for 3 h. The actinomycin C-
treated STO non-dividing cells were extensively
washed in PBS and plated at 35, 000 cells/cm2 in
gelatin-coated tissue culture dish.
Microscopy and Reporter Gene Assay
All microscopy was performed on live cells with a
LEICA DMI3000B microscope following 48 ~ 72 h trans-
duction. Data collection and processing were performed
with LAS 3.8 software.
Lentiviral Titration
Pseudoviral titer was performed using a real time PCR
based kit (LV961A-1, SBI, Mountain View, CA). This kit
measures the copy numbers of integrated gene after
transduction. Briefly, HT1080 cells were transduced in
the presence of 1 × TransDux reagent (LV850A-1, SBI,
Mountain View, CA) for 72 h. Subsequently cells were
lysed and DNAs were isolated according to manufac-
turer’s instructions. PCR reactions were performed with
primers for amplifying a conserved genomic DNA
sequences or WPRE in the transgeneusing Applied
Biosystems 7300 Real time PCR System. PCR condition:
50 °C, 2 min; 95 °C, 10 min; followed by 40 cycles of
95 °C, 15 s and 60 °C for 1 min, followed by a dissoci-
ation step.
Standard Operating Procedure for Lentiviral Packaging
Reagents
The expression constructs CD511B-1 and LV605A-1
(SBI, Mountain View, CA) are packaged into VSVG
pseudotypedviral particles with proteins produced by
the lentiviral packaging plasmid mix (LV500A-1, SBI,
Mountain view, CA). The lentiviralpackaging system con-
sists of an optimized mixture of three plasmids, including
pPACKH1-GAG, pPACKH1-REV and pVSVG. To
produce integrative competent lentiviruse, the pPACKH1-
GAG has a wild-type pol gene. To produce non-
integrative lentiviruses, the pPACKH1-GAG with a
mutated integrase (an integrase domain in pol gene) was
used instead of the wild-type. Other reagents include virus
producer cell lineHEK293TN (LV900A-1, SBI, Mountain
View), transfection reagent PureFection (LV750A-1, SBI,
Mountain View), and virus precipitation solution
(LV810A-1, SBI, Mountain View).
Additional reagents include DMEM high glucose with
sodium pyruvate and l-glutamate (Invitrogen, Cat.
#111995073), Fetal bovine serum (Invitrogen, Cat.
#16000036), Penicillin/Streptomycin (Invitrogen, Cat. #
15070063), Trypsin-EDTA (Sigma, Cat. #T3924),
hematopoietic plate cell counter.
Step-by-step Protocol (bench time 110 min, total time
6 days)
Day 1
Seed 293 TN producer cells (30 min)
18 ~ 24 h prior to transfection, wash cells with pre-
warmed DPBS once and add 2 mlTrypsin-EDTA to
the culture flask. Incubate for 5 min or until cells
become detached from surface and add 10 ml of
complete medium to neutralize the digestion enzyme.
Precipitate cells by centrifugation at 300 rpm for
5 min at room temperature. Re-suspend cell pellet in
5 ml complete medium and count cells. Seed 293TN
cells at 7 ~ 8 × 106/15 cm2 in 20 ml complete culture
medium with antibiotics, until the cell density reaches
70 ~ 80 % confluence for transfection.
Day 2
Transfecting 293TN Producer cells with lentivector
expressing reporter (CD511, LV605) and lenti viral
packaging plasmid mix expressing WT and mutant
integrase (bench time 30 min)
1. Prepare lentivector DNA and packaging plasmid mix
Add 1 ~ 1.6 ml plain DMEM (serum and
antibiotic free) to an Eppendorf tube; add 4.5 μg
lentivector and 45 μl packaging plasmid DNAinto
the DMEM. Mix by pipetting for 10 times.
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2. Prepare transfection mix
Add 55 μl PureFection into the same tube.
Vertex for 10 s and incubate the DMEM-Plasmid-
PureFectionmixture at room temperature for 15 min.
3. Apply transfection mix to producer cells
Add DMEM-Plasmid-PureFectionmixture drop-wise
to the dish, and swirl to disperse evenly; return the
dish to the cell culture incubator at 37 °C with 5 %
CO2; change the medium 12 ~ 24 h after transfection
(optional).
Day 4 and Day 5
Harvest packaged viruses (bench time 30 min; total 2 h)
48 h after transfection, collect the culture medium
containing pseudoviral particles into a 50-ml sterile,
capped conical centrifuge tube and store at 4 °C until
next harvest. Re-fill producer cells with 10 ml fresh
complete medium slowly, and return dishes to the cell
culture incubator.
72 h after transfection, collect the culture medium and
combined it with the collection at 48 h. Centrifuge at
3000 × g for 15 min at room temperature to pellet cell
debris. Transfer the viral supernatant into a new tube
and add 1 volume of cold PEG-it Virus Precipitation
Solution (4 °C) to every 4 volumes of Lentivector-
containing supernatant. Larger volume precipitation of
lentiviral particles can be achieved by using the Corning
250 ml polypropylene centrifuge tube (Cat. #430776),
following manufacturer’s instructions: refrigerate over-
night or for at least 12 h. Lentivirus-containing superna-
tants mixed with PEG-it Virus Precipitate Solution
(LV810A-1, SBI, Mountain View, CA) are stable for up to
4 ~ 5 days at 4 °C.
Day 6
Collect and concentrate psuedotyped viral particles
(bench time 20 min; total 1.2 h)
Centrifuge supernatant/PEG-it mixture at 3000 × g for
30 min at 4°C, and transfer supernatant to a fresh tub.
After centrifugation, the lentivector particles will appear
as a beige or white pellet at the bottom of the vessel.
Spin down residual PEG-it solution by centrifugation at
3000 × g for 5 min; remove all traces of fluid by aspiration,
and avoid disturbing the precipitated lentiviral particles in
pellet. Re-suspend lentiviral pellets from 1/10 to 1/100 of
original volume using cold, sterile PBS or DMEM contain-
ing 25 mM HEPES buffer at 4 °C. Aliquot into cryogenic
vials and store at −70 °C.
Trouble-Shooting Advice
1. Low viral titer (<105 ifu/mL) can be caused by a
number of reasons. The most common ones
include:(1) poor transfection efficiency due to too
high or too low density of producer cells. (2) Poor
quality of lentivector or packaging plasmid DNA.
(3) Inadequate ratios of plasmid mix to the
transfection reagent. To avoid these, plate cells to
achieve 70 ~ 80 % confluency at transfection stage
and use endotoxin-free plasmid purification kit to
prepare lentivector expressing the transgene and
packaging plasmids.
2. If problem remains, other factors to be consideredare:
(1) producer HEK293TN cells are of poor quality due
to over confluence; (2) cells may be contaminated by
mycoplasma; (3) too many passages (>20) of cells.
In those cases, one should revive a new batch of
producer cells and maintain them in the logarithmic
growth phase.
3. Other factors which could affect virus quality are:
The packaging limit for the lentiviral system, which
is ~8.5 kb from 5′→ 3′ LTR. The efficiency of
packaging drops significantly when cDNA size
increases. For a 3 kb insert, the titers and expression
level can be 10-fold less compared to that ofa 1 kb
insert. Repeated sequences can also cause problems
in transgene expression as recently reported [17].
Safety Guide to Packaging and Transduction of Target Cells
The use of HIV-based pseudotypedlentiviruses falls
within NIH Biosafety Level 2 criteria due to the potential
biohazard risk of possible recombination with endogen-
ous viral sequences to form self-replicating virus, or the
possibility of insertional mutagenesis. For a description
of laboratory biosafety level criteria, consult the Centers
for Disease Control Office of Health and Safety Web
site. It is also important to check with the health and
safety guideline at your institution regarding the use of
lentiviruses and always follow standard microbiological
practices.
Additional file
Additional file 1: Figure S1. Schematic representation of the packaging
plasmid, expressing GAG, POL, TAT and ENV. Panel A shows the configuration
of the expression vector for wild-type pol gene, whereas panel B shows the
site-directed mutant, resulting in the change of D116A (denoted by the red
star). (PDF 590 kb)
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